<i>&quot;On Oct 18 the US company Genzyme announced it had formalised an agreement to acquire Cell Genesys for approximately US$350 million. This move follows an agreement by the pharmaceutical division of Japan Tobacco, the world&#x27;s third-largest tobacco company, to purchase the rights to therapeutic and preventive lung-cancer vaccines under development by Cell Genesys and another American biotechnology company, Corixa. If the vaccines are approved, Japan Tobacco will find itself in the unusual position of marketing products that cause, prevent, and treat the same disease.&quot;</i><p>Murray, S. (1999) Kill or cure, confused messages from Japan Tobacco. <i>The Lancet</i>, 354(9188), p.1456.